HCA Healthcare (HCA) Expands Pediatric Gene Editing Access After Journal Study
HCA Healthcare (NYSE:HCA) published new research on a CRISPR-based gene-editing therapy in children aged 5 to 11 with severe blood disorders. The findings, featured in The New England Journal of Medicine, showed positive outcomes in a patient group younger than those covered by existing approvals. The company is extending access to this therapy across its transplant and cellular therapy programs within its hospital network. HCA Healthcare operates one of the largest hospital and specialty...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.